Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Mar 15:8:4.
doi: 10.1186/1476-7961-8-4.

Lack of neo-sensitization to Pen a 1 in patients treated with mite sublingual immunotherapy

Renato E Rossi  1 , Giorgio Monasterolo, Cristoforo Incorvaia, Philippe Moingeon, Franco Frati, Giovanni Passalacqua, Lucilla Rossi, Giorgio W Canonica
Affiliations

Lack of neo-sensitization to Pen a 1 in patients treated with mite sublingual immunotherapy

Renato E Rossi et al. Clin Mol Allergy. .

Abstract

Background: Some studies reported the possible induction of food allergy, caused by neo-sensitization to cross-reacting allergens, during immunotherapy with aeroallergens, while other studies ruled out such possibility.

Objectives: The aim of this study was to evaluate the development of neo-sensitization to Pen a 1 (tropomyosin) as well as the appearance of reactions after ingestion of foods containing tropomyosin as a consequence of sublingual mite immunization.

Materials and methods: Specific IgE to Tropomyosin (rPen a 1) before and after mite sublingual immunotherapy in 134 subjects were measured. IgE-specific antibodies for mite extract and recombinant allergen Pen a 1 were evaluated using the immunoenzymatic CAP system (Phadia Diagnostics, Milan, Italy).

Results: All patients had rPen a 1 IgE negative results before and after mite SLIT and did not show positive shrimp extract skin reactivity and serological rPen a 1 IgE conversion after treatment. More important, no patient showed systemic reactions to crustacean ingestion.

Conclusions: Patients did not show neo-sensitization to tropomyosin, a component of the extract (namely mite group 10) administered. An assessment of a patient's possible pre-existing sensitisation to tropomyosin by skin test and/or specific IgE prior to start mite extract immunotherapy is recommended.

Trial registration: This trial is registered in EudraCT, with the ID number of 2010-02035531.

PubMed Disclaimer

References

    1. De Sario M, Galassi C, Biggeri A, Bisanti L, Ciccone G, Piffer S. Trends in the frequency of asthma and allergies. Epidemiol Prev. 2005;29(Suppl 2):86–90. - PubMed
    1. Nathan RA. The burden of allergic rhinitis. Allergy Asthma Proc. 2007;28:3–9. doi: 10.2500/aap.2007.28.2934. - DOI - PubMed
    1. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. JAllergy Clin Immunol. 1998;102:558–62. doi: 10.1016/S0091-6749(98)70271-4. - DOI - PubMed
    1. Cox L, Li JT, Nelson H, Lockey R. Allergen immunotherapy: a practice parameter second update. J Allergy Clin Immunol. 2007;120:S25–85. doi: 10.1016/j.jaci.2007.06.019. - DOI - PubMed
    1. van Hage-Hamsten M, Valenta R. Specific immunotherapy - the induction of new IgE-specificities? Allergy. 2002;57:375–9. doi: 10.1034/j.1398-9995.2002.00324.x. - DOI - PubMed

LinkOut - more resources